Ghost Tree Capital’s Pfizer PFE Stock Holding History

Ghost Tree Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-158,100	Closed	-$6.5M	–	49
2019 Q2	$6.5M	Buy	+158,100	New	+$6.28M	1.35%	23

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ghost Tree Capital's PFE Position: Q2 2023 in Review

Ghost Tree Capital sold out of Pfizer (PFE) in Q2 2023, closing a stake of 200,000 shares — an estimated $8.16M sold.

Ghost Tree Capital first reported a position in PFE in Q1 2023 and held it in 1 quarter. The position peaked at $8.16M in Q1 2023. 3,041 funds tracked by Wall St. Rank hold PFE as of Q2 2023.

Ghost Tree Capital reported no remaining Pfizer position as of Q2 2023 after selling out during the quarter.
Ghost Tree Capital sold 200,000 Pfizer shares in Q2 2023, an estimated $8.16M.
Ghost Tree Capital first reported a position in Pfizer in Q1 2023 and held it in 1 quarter.
Ghost Tree Capital's Pfizer position peaked at $8.16M in Q1 2023.
3,041 funds tracked by Wall St. Rank held Pfizer as of Q2 2023.

Based on Ghost Tree Capital's 13F filing for Q2 2023, filed 14 Aug 2023.